Home
Post
Share
@CovidAnalysis
Meta AnalysisMeta
Xiannuoxin is a combination of simnotrelvir and ritonavir. Simnotrelvir is a first generation SARS-CoV-2 3CL protease inhibitor Bischof. Ritonavir is a HIV drug used to boost the levels of simnotrelvir in the body by inhibiting its metabolism.
Xiannuoxin was adopted
in 1 country.
Submit updates/corrections .
Summary.
Dec 23 |
Xiannuoxin for COVID-19: real-time meta analysis of 2 studies | |
| Meta analysis using the most serious outcome reported shows 38% [-46‑73%] lower risk, without reaching statistical significance. Currently all studies are RCTs. One study shows significant benefit. Studies to date are from only.. | ||
Jan 15 |
et al., Toxics, doi:10.3390/toxics12010073 | Ritonavir Has Reproductive Toxicity Depending on Disrupting PI3K/PDK1/AKT Signaling Pathway |
| In vitro study on boar spermatozoa showing that the HIV drug ritonavir (part of paxlovid and xiannuoxin) causes reproductive toxicity by disrupting the PI3K/PDK1/AKT signaling pathway. Ritonavir suppressed sperm functions including motili.. | ||
Dec 31 2023 |
et al., European Journal of Pharmaceutical Sciences, doi:10.1016/j.ejps.2023.106598 | A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects |
| RCT 72 healthy subjects evaluating safety, tolerability, and pharmacokinetics of simnotrelvir (SSD8432, SIM0417), a 3CL protease inhibitor, alone or co-administered with ritonavir at various single and multiple ascending oral doses and un.. | ||
Dec 31 2023 |
, E., Aging and disease, doi:10.14336/AD.2023.0318 | Mitigating COVID-19 Mortality and Morbidity in China's Aging Population: A Focus on Available Medications and Future Developments |
| Review focusing on 3CL protease inhibitors. First generation inhibitors like paxlovid and simnotrelvir require boosting with ritonavir, which can cause drug-drug interactions and other issues. Second generation inhibitors like ensitrelvir.. | ||
Oct 13 2023 |
et al., Nature Communications, doi:10.1038/s41467-023-42102-y | Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir |
| In Vitro and mouse study showing the development and preclinical evaluation of the SARS-CoV-2 3C-like protease (3CLpro) inhibitor simnotrelvir (SSD8432, SIM0417, part of xiannuoxin) as an orally bioavailable COVID-19 therapeutic agent... | ||
Sep 30 2023 |
et al., The Lancet Regional Health - Western Pacific, doi:10.1016/j.lanwpc.2023.100835 | Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial |
| 68% faster recovery (p=0.06) and 38% improved viral clearance (p=0.11). RCT 32 adults with asymptomatic, mild or moderate COVID-19 in China showing greater viral load reduction and faster time to symptom alleviation with xuannuoxin (simnotrelvir plus ritonavir) compared to placebo. All adverse events were mild. | ||
Jul 31 2023 |
et al., Progress in Pharmaceutical Sciences, doi:10.20053/j.issn1001-5094.2023.07.002 | XIANNUOXIN®: China’s First Anti-SARS-CoV-2 Drug Targeting 3C-like Protease |
| Review of the development and approval of Xiannuoxin, the first domestic anti-COVID-19 drug targeting the 3C-like protease (3CLpro) approved in China. Xiannuoxin was jointly developed by Simcere Pharmaceutical Group, Shanghai Institute of.. | ||
Jan 29 2023 |
et al., New England Journal of Medicine, doi:10.1056/NEJMoa2301425 (press release 1/29/2023) | Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19 |
| 17% faster recovery (p=0.003). RCT 1,208 outpatients with mild-moderate COVID-19 in China, showing faster symptom resolution (by 35.8 hours) and faster viral clearance with xiannuoxin (simnotrelvir plus ritonavir) twice daily for 5 days. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.